There has been a great deal of concern among investors about Urban Outfitters (NASDAQ: URBN) due to the lifestyle retailer’s dismal performance in the stock market. As the company prepares to publish results for the second quarter of 2020 on August 20 at 4:10 pm ET, the general sentiment is not very optimistic.
Analysts, on average, forecast earnings to be $0.59 per share, down 30% from the year-ago quarter. Revenues are expected to decline by 1% to $982.6 million. In an indication that the pricing challenges that affected sales in the early months of the fiscal year still persist, the management had predicted slower comparable store sales growth and a decline in margins for the to-be-reported quarter.
This time, the bottom-line will be affected by an increase in SG&A expenses and investments made in the e-commerce platform to strengthen multi-channel capabilities.
Nevertheless, the direct-to-customer push and the planned launch of new brands including clothing rental service Nuuly will help the company regain momentum in the future. The management needs to focus on streamlining inventory and easing pricing pressures to enhance profitability in the near term.
In the March quarter, earnings declined in double digits to $0.31 per share, despite revenues growing modestly to $864.4 million. The results came in above the estimates. The impact of muted comparable store performance was partially offset by relatively strong online sales.
Among others in the sector, American Eagle Outfitters (AEO) is scheduled to release its second-quarter earnings on September 4 before the opening bell. Analysts expect earnings to slip to $0.32 per share on revenues of around $1 billion.
Earlier this week, Urban Outfitters’ stock suffered after brokerage B. Riley FBR downgraded it to neutral from buy, citing continued weakness in sales despite the management forecasting an improvement from last year’s lows. The analyst is of the view that the downtrend in profitability might persist through 2022.
A potential rebound in the stock’s performance will depend on the company’s ability to revive the sales momentum. The shares lost consistently in the past twelve months and traded at a two-year low in mid-August. They dropped around 41% since the beginning of the year.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated